Epidemiology and etiology of childhood pneumonia in 2010:estimates of incidence, severe morbidity, mortality, underlying risk factors and causative pathogens for 192 countries by Rudan, Igor et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Epidemiology and etiology of childhood pneumonia in 2010
Citation for published version:
Rudan, I, O'Brien, KL, Nair, H, Liu, L, Theodoratou, E, Qazi, S, Lukši, I, Fischer Walker, CL, Black, RE,
Campbell, H & Child Health Epidemiology Reference Group (CHERG) 2013, 'Epidemiology and etiology of
childhood pneumonia in 2010: estimates of incidence, severe morbidity, mortality, underlying risk factors
and causative pathogens for 192 countries' Journal of Global Health, vol 3, no. 1, pp. 10401.
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Journal of Global Health
Publisher Rights Statement:
Copyright © 2013 by the Journal of Global Health. All rights reserved.
This is an open access article distributed under the Creative Commons Attribution License, which permits
unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is
properly cited.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 28. Apr. 2017
V
IE
W
PO
IN
TS
PA
PE
RS
V
IE
W
PO
IN
TS
PA
PE
RS
journal of
health
global
Igor Rudan1, Katherine L. O’Brien2, 
Harish Nair1, Li Liu2, Evropi 
Theodoratou1, Shamim Qazi3, Ivana 
Lukšić4, Christa L. Fischer Walker2, 
Robert E. Black2, Harry Campbell1 
on behalf of Child Health 
Epidemiology Reference Group 
(CHERG)
1  Centre for Population Health Sciences 
and Global Health Academy, University 
of Edinburgh Medical School, Edinburgh, 
Scotland, UK
2  Department of International Health, Johns 
Hopkins Bloomberg School of Public Health, 
Baltimore, MD, USA
3  Department of Maternal, Newborn, Child 
and Adolescent Health, World Health 
Organization, Geneva, Switzerland
4  Department of Microbiology, Dr Andrija 
Štampar Institute of Public Health, Zagreb, 
Croatia
Correspondence to:
Professor Igor Rudan 
Centre for Population Health Sciences  
The University of Edinburgh Medical School 
Teviot Place 
Edinburgh EH8 9AG 
Scotland, UK 
igor.rudan@ed.ac.uk
Epidemiology and etiology of childhood 
pneumonia in 2010: estimates of incidence, severe 
morbidity, mortality, underlying risk factors and causative 
pathogens for 192 countries
Background The recent series of reviews conducted within the Global 
Action Plan for Pneumonia and Diarrhoea (GAPPD) addressed epidemi-
ology of the two deadly diseases at the global and regional level; it also 
estimated the effectiveness of interventions, barriers to achieving high 
coverage and the main implications for health policy. The aim of this pa-
per is to provide the estimates of childhood pneumonia at the country 
level. This should allow national policy–makers and stakeholders to im-
plement proposed policies in the World Health Organization (WHO) and 
UNICEF member countries.
Methods We conducted a series of systematic reviews to update previ-
ous estimates of the global, regional and national burden of childhood 
pneumonia incidence, severe morbidity, mortality, risk factors and spe-
cific contributions of the most common pathogens: Streptococcus pneu-
moniae (SP), Haemophilus influenzae type B (Hib), respiratory syncytial 
virus (RSV) and influenza virus (flu). We distributed the global and re-
gional–level estimates of the number of cases, severe cases and deaths 
from childhood pneumonia in 2010–2011 by specific countries using an 
epidemiological model. The model was based on the prevalence of the 
five main risk factors for childhood pneumonia within countries (mal-
nutrition, low birth weight, non–exclusive breastfeeding in the first four 
months, solid fuel use and crowding) and risk effect sizes estimated us-
ing meta–analysis.
Findings The incidence of community–acquired childhood pneumonia 
in low– and middle–income countries (LMIC) in the year 2010, using 
World Health Organization's definition, was about 0.22 (interquartile 
range (IQR) 0.11–0.51) episodes per child–year (e/cy), with 11.5% (IQR 
8.0–33.0%) of cases progressing to severe episodes. This is a reduction 
of nearly 25% over the past decade, which is consistent with observed 
reductions in the prevalence of risk factors for pneumonia throughout 
LMIC. At the level of pneumonia incidence, RSV is the most common 
pathogen, present in about 29% of all episodes, followed by influenza 
(17%). The contribution of different pathogens varies by pneumonia se-
verity strata, with viral etiologies becoming relatively less important and 
most deaths in 2010 caused by the main bacterial agents – SP (33%) and 
Hib (16%), accounting for vaccine use against these two pathogens.
Conclusions In comparison to 2000, the primary epidemiological evi-
dence contributing to the models of childhood pneumonia burden has 
improved only slightly; all estimates have wide uncertainty bounds. Still, 
there is evidence of a decreasing trend for all measures of the burden over 
the period 2000–2010. The estimates of pneumonia incidence, severe 
morbidity, mortality and etiology, although each derived from different 
and independent data, are internally consistent – lending credibility to 
the new set of estimates. Pneumonia continues to be the leading cause 
of both morbidity and mortality for young children beyond the neonatal 
period and requires ongoing strategies and progress to reduce the burden 
further.
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Pneumonia is still the leading cause of child mortality glob-
ally [1,2]. However, an increased focus on the reduction of 
child mortality that arose from the United Nation's Millen-
nium Declaration [3] and the Millennium Development 
Goal 4 has renewed the interest in developing more accu-
rate estimates of the causes of child deaths. This should in-
form more effective health policies and track the progress 
of their impact. In 2001, the Child Health Epidemiology 
Reference Group (CHERG) – a group of independent tech-
nical experts funded by The Gates Foundation and work-
ing closely with the World Health Organization (WHO) 
and UNICEF– set out to systematically review and improve 
data collection, methods and estimates of the main causes 
of child deaths for 2000 [4]. Evidence from CHERG esti-
mates – ie, that pneumonia was the leading cause of child 
mortality – contributed to the initiation of a number of 
global efforts, such as the Global Action Plan for Pneumo-
nia (GAPP). GAPP was designed to promote the expansion 
and improvement in community case management, the re-
duction in risk factors for disease and the support for the 
massive roll–out of vaccination against Haemophilus influ-
enzae type b (Hib) and Streptococcus pneumoniae (SP) by 
countries through support from the GAVI Alliance [5,6]. 
Those efforts, alongside economic and social developments 
observed in many low– and middle–income countries over 
the past decade, have all contributed to a substantial reduc-
tion of the burden of morbidity and mortality from child-
hood pneumonia [7].
CHERG's work also led to several Lancet series that had a 
substantial impact on global, regional and national–level 
donors and policy–makers [7–10]. It also inspired similar 
efforts to address the epidemiology and provide estimates 
for other causes of the global burden of different diseases 
[11,12]. The recent series of reviews published in the Lancet 
and PLoS Medicine, conducted by CHERG members in col-
laboration with the WHO, UNICEF and USAID within the 
Global Action Plan for Pneumonia and Diarrhoea (GAPPD), 
addressed the epidemiology and the current global burden 
of the two leading causes of childhood death, pneumonia 
and diarrhea, in the year 2010–11 [13]. The series also es-
timated the importance of risk factors [13], effectiveness of 
interventions [14], barriers to achieving high coverage at 
the community level [15], validity of coverage measures 
[16–17] and main implications for health policy [7].
The recent GAPPD reviews focused at the global and re-
gional level [13]. The aim of this paper is to supplement 
the Lancet's GAPPD series with further information on the 
underlying models and methods, to augment that already 
available, and thereby assure that all input data and de-
tailed descriptions of methods are transparently presented 
and available in an open–access source. Additionally, this 
paper also provides estimates of childhood pneumonia 
burden at the country level to allow national policy–mak-
ers and other stakeholders to implement the proposed pol-
icies in the World Health Organization (WHO) and UNI-
CEF member countries.
Challenges to estimation of childhood 
pneumonia burden
Incidence and severe morbidity. An accurate estimate of 
the global, regional and national burden of childhood pneu-
monia is very difficult to make for a number of reasons. 
First, the incidence of pneumonia can only be properly as-
sessed through longitudinal community based studies [18]. 
Such studies are very scarce in low and middle–income 
countries, where the majority of the pneumonia disease bur-
den occurs, in part because they require a major commit-
ment from both the investigators and research funders in a 
low–resource setting over an extended period of time. Due 
to the seasonal nature of pneumonia incidence, which has 
various peaks in different seasons, studies measuring inci-
dence need to be conducted over full calendar years (or mul-
tiple 12–month periods) [19]. The screening of large num-
bers of children needs to be active, regular and frequent (eg, 
no longer than 2 weeks between home visits), because recall 
bias leads to under–estimation especially in large families 
[19]. In addition to these basic methodological require-
ments, the most fundamental uncertainty with measuring 
the incidence of childhood pneumonia in a community set-
ting comes from the choice of case definition and the accu-
racy of its application by the assessor who establishes the 
diagnosis. Since pneumonia is actually a diagnosis made on 
tissue pathology, there is no clinical definition that is fully 
accurate. In any community–based study on pneumonia 
incidence, the measured entity is not in fact childhood 
pneumonia itself, but rather the incidence of children who 
test positive for the chosen case definition of childhood 
pneumonia [20]. The case definition is based on a number 
of symptoms and signs; although the WHO definition of 
childhood pneumonia (cough or difficulty breathing and an 
elevated respiratory rate, defined according to the child’s 
age) is the most frequently used in field studies, other defi-
nitions are often encountered in the literature confounding 
cross study comparisons of incidence. Depending on the 
combination of sensitivity and specificity of the chosen case 
definition, the burden of “true” pneumonia in the commu-
nity of children can be grossly over– or underestimated [20].
A further problem is that the clinical training of assessors 
differs between the studies and this often affects the appli-
cation of case definitions, unless the study implementation 
is highly controlled. Physicians tend to use their own clin-
ical judgment in addition to the case definition. They will 
be likely to provide more conservative estimates, while 
community health workers may over–diagnose pneumonia 
in a community to the level where they consider a high 
proportion of acute respiratory infections in a child as cas-
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es of “pneumonia” [19]. Moreover, it is important to un-
derstand for each study whether the investigators attempt-
ed to exclude cases of respiratory disease that met the 
clinical pneumonia case definition but were assessed in 
some other way as being bronchiolitis, pertussis, measles, 
or even asthma, malaria or neonatal sepsis.
The effect of these challenges was reflected in the first–ever 
attempt to estimate the incidence of childhood pneumonia, 
which identified only 28 studies that met the minimum 
quality criteria [18]. The incidence of pneumonia reported 
in these studies still ranged 100–fold between their mini-
mum and maximum reported incidence rates per child–
year which could reflect true heterogeneity in the burden 
of disease or more likely also reflects the challenges of stan-
dardizing the epidemiologic study design and its applica-
tion at the field level [18]. Similar, if not greater problems 
are encountered with estimating the incidence of severe, 
life–threatening pneumonia (which requires hospital refer-
ral and treatment) in the community. This estimate cannot 
be based on measures of childhood pneumonia hospital-
izations because parents’ care seeking behavior, access to 
hospitals, and medical professionals’ threshold for admis-
sion varies widely within and across geographic settings 
[19]. There are WHO definitions for severe pneumonia 
(cough and difficulty breathing with lower chest wall in-
drawing) and for very severe pneumonia (cough and dif-
ficulty breathing with danger signs). These definitions are 
useful insofar as they are applied at the community level 
for guiding the case management and referral of children 
to a hospital, hence are purposefully highly sensitive and 
poorly specific for truly life threatening disease. Therefore, 
estimates of the incidence of severe childhood pneumonia 
in the community are particularly rare. Moreover, great 
caution must be applied in making comparisons between 
studies or in combining data across studies to assure that 
only similarly designed and implemented case definitions 
are considered together. The best estimates of pneumonia 
usually come from the control arms of randomized con-
trolled trials of vaccines. This is because severe pneumonia 
is usually an outcome that is being monitored over a mul-
tiple of 12 months, usually with a highly stipulated and 
rigorously implemented case definition. Such studies pro-
vide the best estimates of severe pneumonia in the com-
munity that we have today [19].
Mortality. Estimating mortality that results from childhood 
pneumonia in a community also has its significant meth-
odological challenges. Mortality studies require similar 
study designs to incidence studies, although home visits 
do not need to be as frequent as in the former, because 
care–giver recall of a child death is more accurate and long–
lasting than of an illness episode [21,22]. Identifying the 
exact cause of death can be difficult in an appreciable num-
ber of cases. The assigned cause of death is usually based 
on a verbal autopsy provided by a mother or another fam-
ily member. These are typically based on the report of signs 
and symptoms around the time of death. Many of them are 
not specific to pneumonia, but can also be found in chil-
dren with other conditions, such as sepsis and malaria. In 
addition, many dying children have suffered from chronic 
malnutrition and may have other underlying ailments, 
such as asthma, metabolic disorders, immunodeficient 
conditions (HIV), sequelae of previous injuries, chronic di-
arrhea, or congenital defects [23]. They may develop pneu-
monia in addition to an exacerbation of another ailment, 
or have concomitant malaria or diarrhoea. In such cases, it 
is challenging to assign the death of a child to a single cause 
through verbal autopsy. Furthermore, the clinical signs and 
symptoms of a pneumonia death overlap with those of oth-
er causes of death such as malaria or measles, hence mis-
classification errors are significant. Moreover, there are 
studies that focus exclusively on pneumonia as a cause of 
death, while others are multi–cause mortality studies, doc-
umenting the causes of all child deaths in the community. 
Typically, studies focused exclusively on pneumonia tend 
to over–estimate its contribution to overall child mortality 
[24]. This is because in such studies it is more likely that a 
number of other underlying causes or immediate causes 
may be misclassified as pneumonia. Therefore, multi–cause 
mortality studies are preferred as a source of information 
to single–cause studies [24].
Risk factors. In addition to estimating the incidence, se-
vere morbidity and mortality from childhood pneumonia 
at the global, regional and national level, it is important to 
understand risk factors that contribute to the development 
of childhood pneumonia and that may offer clues to pre-
vention of the disease. However, well–conducted studies 
of pneumonia risk factors in low resource settings are re-
markably scarce. There is wide variation among risk factor 
studies in their focus, study design and outcome: while 
some explore risk factors associated with incidence of 
pneumonia at the community level, others focus on the 
risks that are associated with progression to severe disease 
in those who already have pneumonia [1]. A third type of 
study are those that are hospital–based and investigate risk 
factors associated with progression to death in a child re-
ceiving treatment and compare case–fatality rates among 
different children [1].
Another methodological challenge is that the most com-
monly investigated risk factors for disease or for death are 
commonly identified together among cases. For example, 
undernutrition, use of solid fuels in a household, crowd-
ing, lack of exclusive breastfeeding, low degree of maternal 
education, limited access to secondary care and passive 
care–seeking behavior are all often characteristics of poor 
households, where most of the deaths occur. Because of 
this collinearity, an assessment of the effect size of any par-
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ticular risk factor in isolation from the role of others will 
likely lead to gross over–estimation of the true effect size 
[1,18,19]. Therefore, very large prospective studies are re-
quired, based on multivariable study designs, to ensure an 
adequate number of study participants with heterogeneity 
in the prevalence of risk factors and thereby allow an ac-
curate assessment of the individual role of each risk factor. 
Very few such studies exist; this is a permanent research 
priority, because the effect sizes attributable to individual 
risk factors in different contexts are still poorly understood 
[1,18,19].
Etiological agents. There is a growing need to identify eti-
ological agents that contribute to the disease development 
at each of the three levels of severity – episodes of commu-
nity–acquired pneumonia (incidence), severe pneumonia 
(severe morbidity) and pneumonia deaths (mortality). This 
is because vaccines are now available to prevent infections 
with major pathogens, such and Streptococcus pneumoniae 
(SP), Haemophilus influenzae type b (Hib) and influenza virus 
(flu), while a vaccine against respiratory syncytial virus 
(RSV) is also being actively pursued [25–27]. However, 
precise estimation of the distribution of the episodes, se-
vere episodes and deaths from childhood pneumonia by 
etiological agent is even more difficult than estimation of 
the overall disease burden itself, for a number of reasons. 
First and foremost, the site of infection – the lung –is gen-
erally an inaccessible organ that is in constant contact with 
the external environment through the naso– and oro–phar-
ynx, which are body sites that are sampling and immuno-
logically responding to potential pathogens. Second, the 
procedures needed to collect specimens from potential cas-
es are ones that usually require a hospital facility, meaning 
that studies must be done in places where cases have ac-
cess to a hospital facility. Such studies also require labora-
tory facilities that can process samples in a timely fashion 
and can run a multitude of tests to document presence of 
pathogens in a child [28]. This means that they tend to be 
(teaching) hospital–based and therefore do not sample 
across the whole range of pneumonia cases in a population. 
Most deaths from pneumonia occur in places where no 
hospital facility is available, highlighting the nearly inextri-
cable paradox that appropriate studies cannot be done in 
the places where most of the death burden occurs.
Third, accepting that paradox, even in settings where stud-
ies can be done there are further issues. The choice of bio-
logical samples (specimen) in which the presence of a po-
tential pathogen should be sought means that multiple 
body fluids must be collected. Ideally, for a bacterial diag-
nosis, samples should come from the lung tissue itself (eg, 
by needle aspirate), from a pleural exudate, or a blood cul-
ture sample, but this is often neither feasible nor acceptable 
in a professional or lay community [28]. As an alternative, 
analyses of collected sputum or nasopharyngeal swabs can 
be performed, but their contribution to understanding the 
etiology is complex since the pathogens identified in these 
locations are also commonly found among healthy chil-
dren.
Fourth, the more tests performed, the more agents will be 
found, and statistical methods to disaggregate and associ-
ate individual pathogen contributions to etiology are lack-
ing. This is an increasing problem with modern sensitive 
techniques like PCR–based tests identifying the presence 
of often many co–existing and potentially pathogenic 
agents (whose role in the disease episode is very uncertain). 
Finally, we don't sufficiently understand the interplay be-
tween various pathogens and how a specific time sequence 
(eg, a viral infection, followed by a bacterial superinfection) 
may act to compromise the local and/or systemic immune 
response to cause a serious and life–threatening episode of 
childhood pneumonia by a pathogen that may otherwise 
not cause severe disease. Even with sophisticated expansive 
testing a significant proportion of cases may not have an 
etiology associated with the case. The meaning of this has 
to be assessed. Some of these cases may not have pneumo-
nia at all, while other cases may not be associated with an 
etiology because of statistical methods used, in spite of 
identification of pathogens in the upper respiratory tract; 
finally, some may not be assigned to a causal pathogen be-
cause of laboratory test insensitivity. There remains there-
fore a gap in understanding the etiological spectrum of 
what is clinically defined as pneumonia [25,28].
These complex issues for studying pneumonia etiology are 
being addressed in a large, 7 country pneumonia etiology 
study among children (PERCH) [25]. This study is under 
way and the first results are expected following the comple-
tion of the field work (in early 2014) and an analysis pe-
riod.
Because of the many biologic, epidemiologic, laboratory, 
and statistical challenges of pneumonia etiology observa-
tional studies, the most reliable methods for estimation of 
the proportional contribution of different pathogens to the 
burden of childhood pneumonia are vaccine trials [29]. 
The observed reduction in the incidence of pneumonia (us-
ing various case definitions) following vaccination reveals 
the disease burden attributable to that specific pathogen, 
once the less than 100% vaccine efficacy of the product is 
accounted for. This approach also has its limitations, most-
ly insofar as a vaccine trial can only reveal the burden of 
one pathogen at a time. For some pathogens (such as SP), 
not all disease–causing strains may be included in a strain 
specific vaccine [30]. If the distribution of strains varies by 
factors that also contribute to variation in pneumonia dis-
ease burden (eg, geography, pneumonia case definition, 
malnutrition, HIV), then careful attention must be paid to 
applying the vaccine efficacy measures to the appropriate 
measure of pneumonia disease burden [29]. Also, vaccine–
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based approach may be very useful in understanding the 
causal contribution at the level of incidence and severe 
morbidity, but may be limited in their ability to inform 
about the pathogen contribution to mortality (which is of-
ten a rare event in vaccine trials, where enormous resourc-
es are in place that themselves reduce the risk of death). 
Finally, although it might be ideal to conduct vaccine trials 
in parallel in many geographic regions using a harmonized 
protocol to reveal the geographic variability in contribution 
of pathogens to disease, vaccine trials are not usually de-
signed for the purpose of disease burden estimation; they 
are also very expensive to conduct, which limits the num-
ber of sites where they can be undertaken [31]. They are 
generally not sufficiently large to have acceptable statistical 
power to detect a mortality reduction, as there are relative-
ly few deaths in the study population.
Moreover, after a definite proof of vaccine efficacy and ef-
fectiveness is established, there are significant ethical issues 
regarding the conduct of further trials if they necessitate a 
control arm in which children are not provided what has 
been shown to be a life–saving vaccine. This self–limits the 
accumulation of the evidence towards the importance of 
specific pathogens. An additional layer of complexity 
comes from the notion that the etiological spectrum may 
change markedly with increasing severity of disease: at the 
level of incidence of childhood pneumonia in the commu-
nity, viral causes seem to be responsible for a majority of 
episodes. However, a proportion of these cases will result 
in severe and life–threatening disease. In a sub–sample of 
severe cases, bacterial agents seem to be over–represented. 
Evidence from antibiotic treatment trials, from vaccine tri-
als, and from studies of lung puncture studies provide a 
firm evidence base that episodes of death from pneumonia 
are dominated by bacterial causes. If true, this would sug-
gest that SP and Hib vaccine probe studies (with “proxy” 
endpoints of severe episodes prevented) may under–esti-
mate the importance of these agents as a cause of death. 
Longitudinal studies of mortality in low–income countries 
that have introduced Hib and SP vaccines recently and that 
are achieving high vaccine coverage will likely provide con-
firmatory evidence of that contribution to pneumonia mor-
tality in the coming years [25,26,31].
An overview of previous estimates
One of the earliest attempts at estimating the global burden 
of communicable diseases was provided by Cockburn and 
Assaad in the early 1970s [32]. Bulla and Hitze built on 
their work by specifically addressing the contribution of 
acute respiratory infections [33]. Almost a decade later, Le-
owski [34] used data from 39 countries to estimate that 
acute respiratory infections may have been causing about 
4 million child deaths each year: 2.6 million in infants and 
further 1.4 million in children aged 1–4 years. In the early 
1990s Garenne et al. [35] further refined these estimates 
using an epidemiological model that explored the associa-
tion between all–cause child mortality and the proportion 
of deaths attributable to acute respiratory infections, show-
ing that between 20–33% of child deaths were associated 
with respiratory infections [35,36].
The 21st century has seen a much larger number of efforts, 
mainly designed and led by CHERG and their partners, 
which further improved the understanding of the epidemi-
ology and etiology of childhood pneumonia. The first es-
timate of global incidence of childhood pneumonia was 
provided by Rudan et al. [18] for 2000. In parallel, a re-
fined estimate of childhood pneumonia mortality for the 
same year, based mainly on single–cause studies, was pro-
vided by Williams et al. [37]. The first estimate of pneu-
monia mortality from multi–cause studies was published 
by Black et al. in CHERG's paper on the causes of global 
child mortality in the year 2000 [4]. Then, estimates un-
derwent further refinements and updates. An updated es-
timate of childhood pneumonia mortality for 2008 in post–
neonatal children in low and middle–income countries, 
based on single–cause studies, was provided by Theodora-
tou et al. [38]. Estimates based on multi–cause studies un-
derwent three updates: for the period 2000–2003 by Bryce 
et al. [39]; for 2008 by Black et al. [40]; and for 2010 by 
Li et al. [41].
The first comprehensive assessment of the burden of severe 
pneumonia according to the WHO's definition and the role 
of risk factors was provided by Rudan et al. [1,18]. This 
work was followed by the first attempt to estimate the glob-
al burden of childhood pneumonia on health systems; Nair 
et al. [42] used both published and unpublished informa-
tion to calculate the number of hospitalizations for severe 
pneumonia, a number which is smaller than the estimate 
of cases of severe pneumonia in the community because of 
lack of access and/or care–seeking in many settings.
Once the “envelopes” for the burden of pneumonia inci-
dence, severe morbidity and mortality from pneumonia in 
2000 were provided, a series of efforts attempted to esti-
mate the proportion of the burden at each level of severity 
that can be attributed to the main etiological agents that 
cause pneumonia. O'Brien et al. [43] developed the first 
global, regional and country estimates for the morbidity 
and mortality from Streptococcus pneumoniae, Watt et al. for 
Haemophilus influenzae type b [44], while Nair et al. gener-
ated global and regional estimates for RSV [45] and for in-
fluenza [46].
The estimates of pneumonia incidence, severe pneumonia 
cases, severe pneumonia hospitalizations, pneumonia mor-
tality, and cause specific estimates are based on different 
and almost entirely independent sources of information, 
which allows for assessments of validity and consistency 
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between the various estimates. Validation of these estimates 
can be approached in various ways. A few examples in-
clude: (i) an assessment of the measured proportion of all 
pneumonia cases that are categorized as severe; (ii) the ra-
tio between the estimates of severe episodes and deaths, 
and also (iii) between all pneumonia episodes and deaths. 
These proportions and ratios need to largely support the 
observed case–fatality rates typically seen in both commu-
nity–based and hospital–based data sets from individual 
studies. Moreover, the sum of etiology specific fractions at-
tributed to different pathogens needs to fit within the over-
all burden of incidence, severe morbidity and mortality. For 
the Hib and pneumococcal pathogen specific estimates, 
they must fit within these envelopes by definition, since 
the methodology to estimate the absolute burden was a 
proportional approach – but this was not the approach for 
the estimation of the RSV or influenza burden. The ratios 
between different pathogens were also found to broadly 
reflect those observed in the high quality field studies or 
hospital–based studies further validating the estimates. To-
wards the end of the past decade it was notable that, re-
gardless of all methodological challenges and uncertainty 
inherent to this research, all the major estimates from dif-
ferent sources were increasingly consistent with each other 
and provided a clearer global and regional picture of the 
burden of childhood pneumonia and its causing patho-
gens, albeit with wide uncertainty bounds around the point 
estimates [40–46]. This paper therefore brings all the esti-
mates together and provides an update for 2010–11, in 
which all information is provided in a single analysis, and 
where country–level estimates are also be provided.
METHODS
Many steps are required to develop an internally consistent 
estimate of global, regional and national burden of child-
hood pneumonia based on best available evidence. To ful-
ly explain our approach, we developed a table (Online Sup-
plementary Document) which all input data, assumptions, 
methods, solutions to specific problems or dilemmas, for-
mulae for calculation of different parameters, and the in-
terim and final estimates are provided. In this section, we 
present a summary for those steps, list all sources of data 
and explain the rationale for each subsequent step.
Input data for country–level populations 
and prevalence of risk factors for 
pneumonia incidence
Initially, we list 192 countries by World Health Organiza-
tion's regional classification, with 6 main regions (the 
Americas (AMRO), Africa (AFRO), Eastern Mediterranean 
region (EMRO), European region (EURO), Western Pacif-
ic region (WPRO) and South–East Asian region (SEARO)) 
and further divisions by the level of development into “A”, 
“B”, “C”, “D” and “E” sub–regions [47]. For each country, 
an estimate of the population of children under the age of 
5 years in 2010 was obtained from the UN's Population 
Division [48]. Then, the 5 most important risk factors for 
childhood pneumonia incidence were identified. They 
were selected based on consistently significant effects in 
multivariate study designs and previous meta–analyses 
[1,18]. They are: malnutrition (weight–for–age z<–2), low 
birth weight (≤2500 g), non–exclusive breastfeeding (in the 
first 4 months), solid fuel use (“yes”) and crowding (7 or 
more persons sharing the same household) [1,18]. The 
data on the prevalence of exposure to each of those 5 risk 
factors in each country in the year 2010(or the closest year 
with available data) was obtained from the recent Demo-
graphic and Health Surveys (DHS) and Multiple Indicator 
Cluster Surveys (MICS) [49,50]. For all countries in which 
data on the prevalence of exposure were not available, the 
prevalence was imputed based on the regional mean value, 
which was weighted by population size of all countries 
with any data. The effect size of each risk factor on pneu-
monia incidence was assessed through meta–analysis of the 
studies that reported multivariable analyses of risk factor's 
odds ratios (OR) in low and middle–income countries. The 
meta–estimates of odds ratios assigned to each risk factor 
were: 1.8 for malnutrition, 1.4 for low birth weight, 1.3 for 
non–exclusive breastfeeding, 1.8 for use of solid fuels and 
2.0 for crowding. In high–income countries, where less 
than 2% of all cases of community–acquired pneumonia 
occur, we did not use the model based on risk factors but 
rather applied “flat” rates of incidence for “A”, “B” and “C” 
regions based on several high–quality studies (see Online 
Supplementary Document), and which ranged between 
0.015 and 0.060 episodes/child–year (see later). For the 
proportion of severe episodes in each high–income region 
we used one single rate which was the median of all avail-
able studies (26.7%, see later).
Computation of country–level incidence of 
pneumonia and severe pneumonia
In all LMIC countries, we multiplied the number of chil-
dren in each country by the prevalence of exposure to each 
of the 5 risk factors. This provided an estimate of the ab-
solute number of exposed children in each country who 
were at excess risk of developing childhood pneumonia in 
the year 2010. We then calculated the proportion (ie, a 
weighted mean) of all children in each LMIC region and 
country exposed to each of the 5 risk factors; then, in each 
country, we multiplied the proportion of children who 
were above, or below, the regional exposure level with the 
meta–estimate of the odds ratio attributable to each of the 
5 risk factors.
The number of pneumonia cases in each low and middle–
income country (LMIC) was calculated using a model 
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based on the epidemiological concept of potential impact 
fraction [51], as follows:
N Pop Incl Ryrs LMIC RF n RFn= ( ) × ( ) × + ( ) ×< = →( )5 11 Σ Prev -PrevRFnLMIC RRFn -1( ) { }
where N is the number of new episodes of childhood pneu-
monia per year in each country, Pop<5yrsis the population of 
children aged 0–4 years in each LMIC, IncLMIC is the esti-
mated incidence of clinical pneumonia for all LMIC, Pre-
vRFn is the prevalence of exposure to n–th risk factor among 
those under 5-year in the country of interest, PrevRFnLMIC is 
the prevalence of exposure to nth risk factor among under–
fives in all LMIC, and RRRFn is the relative risk for develop-
ing clinical pneumonia associated with the nth risk factor 
(see Online Supplementary Document for further details).
The incidence of pneumonia for all LMIC was derived 
from35 community–based studies published between1990 
and 2012 (references shown in Online Supplementary 
Document), by using the median value (0.22 episodes/
child–year) and inter–quartile range (IQR) 0.11–0.51 as 
confidence intervals.
Although there are many possible methods to distribute 
the global and/or regional burden estimate among individ-
ual countries, the approach used above is our preferred so-
lution because it is epidemiologically sound and biologi-
cally intuitive insofar as it is based on the country specific 
prevalence of known risk factors for pneumonia, and be-
cause it can be explained in a transparent and accessible 
manner. Although more complex models exist, our experi-
ence is that these sometimes result in implausibly high or 
low estimates for some countries, the cause of which is dif-
ficult to disentangle. This model, because of its computa-
tional simplicity and epidemiologic basis, has not suffered 
from this problem. The model has also been shown to dis-
tribute a known overall burden by specific countries in the 
absence of truly nationally representative information from 
many (or, in this case, from most) countries in a way which 
is consistent with clinical and epidemiologic knowledge.
The proportion of cases of severe pneumonia (based on the 
WHO definition that requires presentation of lower chest 
wall indrawing, and represents an indication for hospital-
ization) for LMIC was computed based on 9 community–
based studies in LMIC that reported the proportion of se-
vere pneumonia episodes among all pneumonia episodes 
(references shown in Online Supplementary Document). 
The median value was 11.5% (IQR 8.0–33.0%). The inci-
dence of pneumonia in high–income countries, based on 
a smaller number of very large, high–quality studies (refer-
ences shown in Online Supplementary Document), was 
also estimated using medians (and IQR): it was 0.015 e/cy 
in EUROA and AMROA regions; 0.030 e/cy in EURO Band 
0.060 in EURO C. The mean of those values (for the whole 
HIC region), weighted by their under–five population size, 
was0.024 e/cy [52]. Approximately 26.7% (IQR 20.0–
46.7%) of those episodes are estimated to progress to severe 
pneumonia, based on several studies from high–income 
countries (references shown in Online Supplementary Doc-
ument). The estimates for the number of incident and severe 
pneumonia episodes derived in this way did not account for 
the use and effect of pneumococcal conjugate vaccine (PCV) 
and Hib vaccination coverage in 2010 at this stage of the es-
timation process, so the values from this step are not consid-
ered the final pneumonia burden numbers.
Etiologic fractions of pneumonia and 
severe pneumonia cases
We split both the incidence and severe morbidity of child-
hood pneumonia by etiological agents while adjusting for 
the effects PCV and Hib vaccines according to country spe-
cific coverage values provided for 2010 by the UNICEF 
[53]. In doing so, we used the proportional contributions 
to all childhood pneumonia and severe childhood pneu-
monia from previous burden estimates on SP [43], Hib 
[44], RSV [45] and influenza [46] and accounted for vac-
cine efficacy and serotype distribution of pneumococcal 
disease as well as dual use of Hib and PCV where relevant. 
All further details are available in Online Supplementary 
Document.
Country–specific estimates of the number 
of deaths from childhood pneumonia
This was available for 2010 from Li et al. [41]. A more re-
cent update was made available by the UN Inter–Agency 
Group for Child Mortality Estimation IGME in UNICEF's 
2012 report, which we term a “2010–2011” estimate [54]. 
Given the important focus on child mortality, and relative-
ly minor differences compared with the Li 2010 estimates, 
we elected to use the 2010–11estimates for the envelopes 
of pneumonia deaths by country. The same decision was 
made in the Lancet's series [13]. The only methodological 
problem with this decision is a separation of Sudan and in-
troduction of the new country – South Sudan from 2011, 
but we presented our results on mortality for both Sudan 
nations combined, and kept it within the EMRO region, 
although South Sudan belongs to AFRO region in the new 
classification [47].
Proportional split of pneumonia deaths by 
etiological agent
To estimate the fraction of pneumonia deaths attributable 
to SP and Hib, we used the meta–analysis of the efficacy of 
PCV and Hib vaccines against chest X–ray confirmed pneu-
monia as has been described earlier (43,44), based on the 
assumption that the etiologic fraction of these bacteria 
among these particular cases approximates the etiologic 
fraction among the deaths. The values (33.0% for SP and 
21.3% for Hib) were then adjusted by country for the use 
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of PCV and Hib vaccine to derive the final SP and Hib pro-
portions [43,44,53]. Since the global disease burden esti-
mates for flu and RSV pneumonia were not able to give 
point estimates and confidence intervals due to lack of data 
we did not attempt to go beyond the published global and 
regional estimates for these conditions and so did not at-
tempt to derive national–level estimates [45,46].
RESULTS
Table 1 presents our estimates for 192 countries, grouped 
by the WHO regions: Africa (AFRO), the Americas 
(AMRO), Eastern Mediterranean region (EMRO), South–
East Asian region (SEARO), Western Pacific region (WPRO) 
and European region (EURO). Several main results emerge 
from the presented figures. First, the population of under–
five children in the world increased from 604.9 million to 
633.5 million between 2000 and 2010, but the majority of 
the increase was observed in low– and middle–income 
countries (523.3 to 547.3 million), and only a smaller share 
in high–income countries (81.6 to 86.2 million). Holding 
all else constant, an increase in total child population 
would increase the absolute number of pneumonia cases; 
however, the number of cases has decreased over the past 
decade, because the incidence has decreased substantially. 
When presenting our estimates of incidence for 2000, we 
reported on 28 studies published between 1960 and 2000 
that suggested an estimated incidence of 0.29 (0.21–0.71) 
episodes per child–year globally [18]. In this most recent 
estimate, we used 35 studies published between 1990 and 
2010 with a median incidence of 0.22 (0.11–0.51). This is 
a notable reduction, of nearly 25%, over a period of a de-
cade. In high–income countries we gathered more data 
over the past decade, and a very rough estimate of 0.05 e/
cy, based on two very large, but historic studies in the USA 
and the UK [55,56], was refined and replaced with the data 
from 9 more contemporary studies, which provide a com-
munity–based incidence of 0.015 e/cy (0.012–0.020) for 
HIC only (WHO's “A” regions), a more plausible estimate 
for the modern industrial societies.
The 2000 estimate of the proportion of pneumonia epi-
sodes that are severe was 8.6% (7.0–13.0%), and was based 
on 6 studies, all of them from LMIC [18]. The estimate for 
2010 is based on 9 studies and brings the estimate for 
LMIC upward, to 11.5% (8.0–33.0%). In HIC for 2000, 
we did not have an evidence–based estimate for the pro-
portion of pneumonia episodes in the community that de-
velop into severe cases. In this current analysis, we found 
9 more recent studies from HIC that show a much higher 
estimate of the proportion – 26.7% (20.0–46.7%). How-
ever, many of them come from hospital–based studies, 
where more severe episodes are likely to be clustered, and 
a lower threshold for severity is generally applied. Still, an 
increasing trend in the proportion of severe episodes in 
LMICs seems consistent with a higher proportion expected 
in HICs. Nevertheless, in an effort not to overestimate the 
severe pneumonia burden we elected to use the proportion 
of pneumonia episodes developing into severe disease from 
the LMIC in all HIC also.
An analysis of the prevalence of exposure to the 5 main risk 
factors in the year 2010 in comparison to 2000 shows that 
the prevalence of malnutrition declined in all LMICs from 
26.9% to 21.9%, low birth weight from 15.9% to 8.8%, 
non–exclusive breastfeeding from 64.4% to 52.6% and sol-
id fuel use from 65.5% to 52.2% [49,50]. The exposure to 
all of those risk factors fell by 20–30%, which provides 
plausibility to the finding that our estimate of the incidence 
of pneumonia fell by 25% between 2000 and 2010 in 
LMICs. We could not perform a similar comparison with 
the crowding risk factor, because of the change of the def-
inition of crowding from “5 or more” to “7 or more” resi-
dents in the same household between surveys done in 2000 
and 2010.
This study also exposed rather dramatic changes in the im-
portance of different etiological agents along the spectrum 
of pneumonia episode severity. At the level of all incident 
episodes in a community, RSV is the most common patho-
gen, present in about 28.8% of all episodes, followed by 
influenza (17.0%), while SP (adjusted for vaccine use of 
both Hib and PCV) is estimated to account for only 6.9% 
of cases and Hib (adjusted for vaccine use) in 2.8% of cas-
es. However, at the level of severe episodes, RSV's contri-
bution decreased to 22.6% and influenza to 7.0%, while 
SP rose to 18.3% and Hib to 4.1%. Bacterial etiologies be-
come even more important in the subgroup of the children 
who eventually die of the disease, with the dominant causes 
being SP (32.7%) and Hib (15.7%). Again, both of these 
estimates account for Hib and PCV vaccine use in 2010.
DISCUSSION
Although there is seemingly more evidence used in this 
study than there was available in the previous studies of 
global childhood pneumonia morbidity [1,18], the increase 
in evidence is only slight: 35 studies in 1990–2010 to es-
timate global pneumonia incidence, in comparison to 28 
studies for the period 1960–2000 [18]. This also means 
that the studies published between 1990 and 2000 were 
used to produce both estimates. However, the most recent 
studies (those published after 2000) are consistently show-
ing a substantially lower incidence of community–based 
pneumonia than was the case historically, which implies 
that the burden of morbidity is steadily decreasing. This 
also suggests that the estimates presented in this paper 
maybe more closely related to the situation in the year 2000 
rather than 2010, because we used the information from 
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Table 1. Estimates of the number of new episodes (incidence) of community–acquired pneumonia in 2010 in children 0–4 years of age 
in 192 countries, shown as national–level totals (incidence, all ALRI) and by causative pathogens (SP, Hib, RSV and flu); estimates of 
the number of new severe episodes (according to WHO's definition) in the year 2010 that require hospitalizations, shown as national–
level totals (severe episodes, all ALRI) and by causative pathogens (SP, Hib, RSV and flu); and estimates of the number of child deaths 
attributable to pneumonia in 2011 (mortality, all ALRI) and the proportion of deaths caused by SP and Hib
New episodes (incidence) New severe episodes (severe morbidity) Deaths (mortality)
Country
WHO 
Region
Popula-
tion 0–4 
years
All  
ALRI
SP Hib RSV FLU
All  
ALRI
SP Hib RSV FLU
All 
ALRI
SP Hib
RSV, 
FLU*
AFRO REGION
Algeria AfroD 3446548 470713 34251 4697 135754 80351 53790 10297 783 7315 2251 2440 804 148 N/A
Angola AfroD 3377576 856794 62241 9674 247099 146255 97936 18712 1613 13293 4090 20429 6733 1398 N/A
Benin AfroD 1506408 424074 30705 5895 122303 72389 48501 9231 983 6558 2018 6281 2070 522 N/A
Burkina Faso AfroD 2955148 1047365 76085 11826 302060 178785 119719 22874 1972 16250 5000 17933 5911 1227 N/A
Cameroon AfroD 3054802 790160 56858 14815 227882 134880 90462 17094 2470 12143 3736 13341 4397 1463 N/A
Cape Verde AfroD 50634 9874 691 395 2848 1686 1136 208 66 148 45 39 13 8 N/A
Chad AfroD 2006165 678297 48155 19812 195621 115785 77827 14477 3304 10285 3164 14683 4840 2390 N/A
Comoros AfroD 122296 38380 2769 645 11069 6552 4392 832 108 591 182 377 124 37 N/A
Equ. Guinea AfroD 107207 16341 1144 654 4713 2789 1879 344 109 244 75 402 132 85 N/A
Gabon AfroD 185179 36186 2579 943 10436 6177 4149 775 157 551 170 291 96 43 N/A
Gambia AfroD 287078 79805 2667 802 23016 13623 8746 802 134 1338 412 987 171 56 N/A
Ghana AfroD 3532887 795448 57857 8199 229407 135783 90905 17394 1367 12357 3802 7808 2573 490 N/A
Guinea AfroD 1657883 546525 39262 10948 157618 93292 62586 11804 1826 8385 2580 7689 2534 895 N/A
Guin.–Bissau AfroD 240350 75199 5429 1216 21687 12836 8605 1632 203 1159 357 1592 525 152 N/A
Liberia AfroD 680701 212990 15195 5418 61426 36357 24419 4568 903 3245 999 1611 531 232 N/A
Madagascar AfroD 3305278 1051407 76189 13932 303226 179475 120231 22906 2323 16272 5007 8004 2638 637 N/A
Mali AfroD 2911668 932894 67350 15086 269047 159245 106745 20248 2516 14384 4426 23947 7893 2292 N/A
Mauritania AfroD 513267 144982 10415 2904 41813 24748 16603 3131 484 2224 684 2099 692 244 N/A
Mauritius AfroD 84433 13518 985 117 3899 2307 1544 296 20 210 65 20 7 1 N/A
Niger AfroD 3084517 1127652 81210 20418 325215 192490 129082 24415 3405 17344 5337 19004 6264 2018 N/A
Nigeria AfroD 26568927 7339761 513783 293590 2116787 1252897 844072 154465 48956 109729 33763 121201 39948 25767 N/A
S. Tome & P'e AfroD 23490 5118 373 46 1476 874 585 112 8 80 25 79 26 4 N/A
Senegal AfroD 2081483 591373 42853 7836 170552 100947 67625 12883 1307 9152 2816 4612 1520 367 N/A
Seychelles AfroD 5623 862 63 7 248 147 98 19 1 13 4 2 1 0 N/A
Sierra Leone AfroD 969597 315676 22866 4286 91041 53886 36101 6874 715 4883 1503 7262 2393 591 N/A
Togo AfroD 862745 280487 20292 4082 80893 47879 32083 6101 681 4334 1333 3321 1095 288 N/A
Zimbabwe AfroD 1692247 349031 25271 4852 100661 59580 39918 7598 809 5397 1661 2461 811 205 N/A
Botswana AfroE 225120 47818 3347 1913 13791 8162 5499 1006 319 715 220 159 52 34 N/A
Burundi AfroE 1184632 349477 25440 3373 100789 59656 39933 7648 562 5433 1672 7259 2393 428 N/A
Cen. Afr. Rep. AfroE 651222 195417 13981 4538 56358 33358 22394 4203 757 2986 919 3911 1289 520 N/A
Congo AfroE 623244 168619 12244 1959 48630 28783 19275 3681 327 2615 805 2001 659 141 N/A
Cote d'Ivoire AfroE 2969425 985611 71421 13060 284250 168244 112707 21472 2178 15253 4693 11003 3626 875 N/A
D. Rep. Congo AfroE 11848026 3671614 263117 80589 1058894 626745 420631 79104 13438 56194 17291 86897 28641 10986 N/A
Eritrea AfroE 861496 208035 15163 1802 59997 35512 23766 4559 301 3238 996 2419 797 129 N/A
Ethiopia AfroE 11931668 3367561 240540 82471 971205 574843 386005 72317 13752 51372 15807 37269 12284 5196 N/A
Kenya AfroE 6664323 1645189 119118 22871 474473 280834 188157 35812 3814 25440 7828 17064 5624 1419 N/A
Lesotho AfroE 274307 58335 4224 811 16824 9958 6672 1270 135 902 278 607 200 50 N/A
Malawi AfroE 2714859 658512 47877 7004 189915 112408 75261 14394 1168 10225 3146 6932 2285 448 N/A
Mozambique AfroE 3876419 1155781 83373 19438 333327 197292 132266 25065 3241 17806 5479 13167 4340 1307 N/A
Namibia AfroE 286374 63796 4619 887 18399 10890 7296 1389 148 987 304 287 95 24 N/A
Rwanda AfroE 1830654 397910 13638 3991 114757 67923 43646 4100 666 6659 2049 4145 734 236 N/A
South Africa AfroE 5041132 705554 33436 14342 203482 120438 78749 10052 2392 11357 3494 5156 1218 583 N/A
Swaziland AfroE 156715 28802 2091 344 8306 4916 3293 629 57 446 137 471 155 34 N/A
Uganda AfroE 6465275 1745727 126241 25969 503468 297996 199697 37953 4330 26961 8296 21181 6981 1876 N/A
U. R. Tanzania AfroE 8009544 2151379 156285 24291 620458 367240 245913 46986 4051 33378 10270 17467 5757 1195 N/A
Zambia AfroE 2412190 576056 41709 8008 166135 98333 65882 12539 1335 8908 2741 6141 2024 511 N/A
AMRO REGION
Canada AmroA 1884546 25275 866 271 13709 8032 6438 604 105 3774 755 27 5 2 N/A
Cuba AmroA 569056 8208 598 79 4452 2609 2178 417 31 1140 228 63 21 4 N/A
USA AmroA 21650217 313322 22733 3845 169946 99574 83169 15868 1489 43355 8671 799 263 59 N/A
Antigua & B'a AmroB 7756 686 50 6 198 117 78 15 1 41 8 0 0 0 N/A
Argentina AmroB 3385831 311588 22663 3212 89862 53188 35609 6814 536 18616 3723 952 314 60 N/A
Bahamas AmroB 25507 2514 182 23 725 429 287 55 4 151 30 25 8 1 N/A
Barbados AmroB 14562 1377 60 19 397 235 153 18 3 87 17 4 1 0 N/A
Belize AmroB 36599 4795 349 46 1383 819 548 105 8 287 57 9 3 1 N/A
Brazil AmroB 15156449 1497706 95518 14711 431938 255658 169535 28717 2453 91150 18230 3079 916 181 N/A
Chile AmroB 1219437 88722 6448 973 25588 15145 10141 1938 162 5296 1059 145 48 10 N/A
Colombia AmroB 4497661 488486 31421 6092 140879 83385 55372 9446 1016 29585 5917 1530 459 113 N/A
Costa Rica AmroB 362979 37185 1272 425 10724 6348 4080 382 71 2389 478 24 4 2 N/A
Dominica AmroB 5924 703 51 6 203 120 80 15 1 42 8 0 0 0 N/A
Dominican R. AmroB 1054063 121820 8813 1773 35133 20795 13934 2650 296 7239 1448 587 193 51 N/A
El Salvador AmroB 616802 72388 3616 829 20877 12357 8079 1087 138 4515 903 221 54 15 N/A
Grenada AmroB 9687 1021 74 10 295 174 117 22 2 61 12 0 0 0 N/A
Guyana AmroB 64818 7186 523 72 2072 1227 821 157 12 429 86 19 6 1 N/A
Honduras AmroB 966002 184407 13435 1658 53183 31478 21068 4039 277 11036 2207 478 157 26 N/A
Jamaica AmroB 246543 31065 2264 269 8959 5303 3549 681 45 1860 372 104 34 6 N/A
Mexico AmroB 11094854 1110027 40375 11872 320132 189482 122060 12138 1980 71108 14222 4069 759 248 N/A
Panama AmroB 345142 38834 2112 415 11200 6629 4354 635 69 2404 481 128 33 8 N/A
Paraguay AmroB 740282 139661 10141 1623 40278 23840 15965 3049 271 8330 1666 368 121 26 N/A
St. Kitts & N's AmroB 4582 441 32 4 127 75 50 10 1 26 5 0 0 0 N/A
Saint Lucia AmroB 15115 1492 109 14 430 255 170 33 2 89 18 0 0 0 N/A
St. Vinc. & G's AmroB 9254 967 70 8 279 165 110 21 1 58 12 1 0 0 N/A
Suriname AmroB 47543 6578 477 85 1897 1123 752 143 14 392 78 20 7 2 N/A
Trinidad & Tobago AmroB 95484 9784 710 114 2822 1670 1118 214 19 584 117 38 13 3 N/A
Uruguay AmroB 246446 17570 647 188 5067 2999 1933 194 31 1125 225 53 10 3 N/A
Venezuela AmroB 2926202 308502 22291 4789 88972 52661 35295 6702 799 18310 3662 927 305 85 N/A
Bolivia AmroD 1234922 137114 9915 2040 39544 23405 15685 2981 340 8145 1629 1909 629 169 N/A
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New episodes (incidence) New severe episodes (severe morbidity) Deaths (mortality)
Country
WHO 
Region
Popula-
tion 0–4 
years
All  
ALRI
SP Hib RSV FLU
All  
ALRI
SP Hib RSV FLU
All 
ALRI
SP Hib
RSV, 
FLU*
Ecuador AmroD 1469919 163860 10901 1437 47257 27971 18596 3277 240 9934 1987 712 219 38 N/A
Guatemala AmroD 2167408 481781 35042 4966 138946 82240 55058 10535 828 28785 5757 2012 663 126 N/A
Haiti AmroD 1237203 345081 24156 13803 99521 58905 39684 7262 2302 19842 3968 4090 1348 870 N/A
Nicaragua AmroD 677569 141434 10304 1272 40790 24143 16159 3098 212 8464 1693 503 166 28 N/A
Peru AmroD 2909336 313170 12566 3545 90318 53458 34584 3778 591 19904 3981 1040 211 67 N/A
EMRO REGION
Bahrain EmroB 93006 9763 327 91 2816 1667 1070 98 15 227 101 5 1 0 N/A
Cyprus EmroB 63553 7253 528 70 2092 1238 829 159 12 156 69 1 0 0 N/A
Iran (Isl. Rep.) EmroB 6149331 729564 51069 29183 210406 124537 83900 15354 4866 15102 6712 4168 1374 886 N/A
Jordan EmroB 816013 87843 6400 790 25334 14995 10036 1924 132 1893 841 268 88 15 N/A
Kuwait EmroB 281414 29357 994 284 8467 5011 3218 299 47 681 303 38 7 2 N/A
Lebanon EmroB 321684 35518 2569 517 10243 6063 4063 773 86 760 338 49 16 4 N/A
Libyan A. J. EmroB 715540 80748 5883 726 23288 13784 9225 1769 121 1740 773 60 20 3 N/A
Oman EmroB 281883 32111 1074 300 9261 5481 3518 323 50 746 332 25 4 1 N/A
Qatar EmroB 90524 9669 331 97 2788 1650 1061 100 16 224 100 4 1 0 N/A
Saudi Arabia EmroB 3145187 337985 11445 3273 97475 57694 37052 3441 546 7842 3485 372 65 20 N/A
Syrian A. R. EmroB 2493561 280849 20309 4178 80997 47941 32127 6106 697 6006 2669 572 189 51 N/A
Tunisia EmroB 868231 99837 6989 3993 28793 17042 11481 2101 666 2067 919 209 69 44 N/A
U. A. Emir. EmroB 420630 46752 1660 517 13483 7981 5137 499 86 1079 480 14 3 1 N/A
Afghanistan EmroD 5545968 2040302 146694 39565 588423 348280 233617 44102 6598 43379 19280 30913 10189 3494 N/A
Djibouti EmroD 113169 24926 1808 306 7189 4255 2850 544 51 535 238 446 147 33 N/A
Egypt EmroD 9008118 680363 47625 27215 196217 116138 78242 14318 4538 14084 6259 4765 1570 1013 N/A
Iraq EmroD 5188175 893131 62519 35725 257579 152457 102710 18796 5957 18488 8217 7568 2494 1609 N/A
Morocco EmroD 3021924 385554 27959 3343 111194 65814 44029 8406 557 8316 3696 3103 1019 165 N/A
Pakistan EmroD 21418111 6728235 487755 86960 1940423 1148510 769337 146640 14501 144236 64105 64853 21376 5039 N/A
Somalia EmroD 1667479 650669 45547 26027 187653 111069 74827 13693 4340 13469 5986 18089 5962 3846 N/A
Sudan EmroD 6391368 2061300 148754 34001 594479 351864 235876 44722 5670 43989 19550 26894 8864 3681 N/A
Yemen EmroD 4057096 1150463 83436 14494 331793 196384 131540 25084 2417 24673 10966 15193 5008 1152 N/A
SEARO REGION
Indonesia SearoB 21578876 3918360 274285 156734 1130055 668864 450611 82462 26135 99135 22531 19147 6311 4071 N/A
Sri Lanka SearoB 1892699 433688 31610 3757 125076 74030 49545 9503 626 11425 2597 298 98 16 N/A
Thailand SearoB 4360687 648021 45361 25921 186889 110617 74522 13638 4322 16395 3726 903 298 192 N/A
Timor Leste SearoB 192839 67370 4716 2695 19429 11500 7748 1418 449 1704 387 489 161 104 N/A
Bangladesh SearoD 14707333 4484527 326317 44752 1293338 765509 512461 98105 7462 117940 26805 18310 6035 1114 N/A
Bhutan SearoD 70891 12773 894 511 3684 2180 1469 269 85 323 73 152 50 32 N/A
DPR of Korea SearoD 1704446 393494 27545 15740 113484 67169 45252 8281 2625 9955 2263 1744 575 371 N/A
India SearoD 127960004 35361230 2475286 1414449 10198179 6036162 4066541 744177 235859 894639 203327 388144 127932 82519 N/A
Maldives SearoD 25984 4061 284 162 1171 693 467 85 27 103 23 6 2 1 N/A
Myanmar SearoD 3956305 1213300 84931 48532 349916 207110 139530 25534 8093 30697 6976 9129 3009 1941 N/A
Nepal SearoD 3506023 832451 58272 33298 240079 142099 95732 17519 5552 21061 4787 5501 1813 1170 N/A
WPRO REGION
Australia WproA 1457527 32776 1204 385 17778 10416 8374 841 149 2724 1654 38 7 3 N/A
Brunei D'lam WproA 37385 899 65 9 488 286 239 46 3 70 42 3 1 0 N/A
Japan WproA 5430793 135770 9504 5431 73642 43148 36251 6634 2103 10150 6163 231 76 49 N/A
New Zealand WproA 311974 7036 264 90 3816 2236 1800 184 35 583 354 31 6 2 N/A
Singapore WproA 230550 5764 403 231 3126 1832 1539 282 89 431 262 9 3 2 N/A
Cambodia WproB 1491690 373583 27150 4096 107741 63771 42699 8162 683 12489 7583 2101 693 140 N/A
China WproB 81595595 6488544 454198 259542 1871296 1107594 746183 136551 43279 208931 126851 43089 14202 9161 N/A
Cook Islands WproB 2096 210 15 2 61 36 24 5 0 7 4 0 0 0 N/A
Fiji WproB 89552 14426 1051 125 4161 2463 1648 316 21 484 294 30 10 2 N/A
Kiribati WproB 9948 1625 118 18 469 277 186 35 3 54 33 19 6 1 N/A
Lao Peop's DR WproB 682861 212441 15325 3573 61268 36264 24312 4607 596 7049 4280 1076 355 107 N/A
Malaysia WproB 2828151 285716 20781 2945 82400 48772 32652 6248 491 9559 5804 199 66 12 N/A
Marshall Isl. WproB 5400 934 59 10 269 159 106 18 2 32 19 5 2 0 N/A
Micronesia WproB 13237 2620 118 50 756 447 292 35 8 91 55 23 5 2 N/A
Mongolia WproB 296799 60292 4389 582 17388 10292 6889 1320 97 2019 1226 332 109 20 N/A
Nauru WproB 1025 97 7 1 28 16 11 2 0 3 2 1 0 0 N/A
Niue WproB 152 15 1 0 4 3 2 0 0 1 0 0 0 0 N/A
Palau WproB 2046 211 12 4 61 36 24 3 1 7 4 0 0 0 N/A
Papua N. G. WproB 962437 166267 11905 3755 47951 28382 19051 3579 626 5476 3325 2038 672 264 N/A
Philippines WproB 11254421 2428448 170059 96399 700364 414536 279254 51127 16075 78227 47495 8974 2958 1896 N/A
R. of Korea WproB 2371820 249811 17487 9992 72045 42643 28728 5257 1666 8044 4884 56 18 12 N/A
Samoa WproB 22338 3377 245 43 974 576 386 74 7 113 68 7 2 1 N/A
Solomon Isl. WproB 79962 19101 1381 290 5509 3261 2185 415 48 635 386 59 20 5 N/A
Tonga WproB 13792 2223 162 19 641 379 254 49 3 75 45 4 1 0 N/A
Tuvalu WproB 1015 126 9 2 36 22 14 3 0 4 3 0 0 0 N/A
Vanuatu WproB 33152 8344 584 334 2406 1424 960 176 56 269 163 9 3 2 N/A
Viet Nam WproB 7185862 1728193 124101 35174 498411 295003 197920 37310 5865 57086 34660 3553 1171 420 N/A
EURO REGION
Andorra EuroA 4001 58 4 1 31 18 15 3 0 9 2 0 0 0 N/A
Austria EuroA 386431 5604 406 78 3040 1781 1488 283 30 913 186 5 2 0 N/A
Belgium EuroA 616259 8882 647 80 4817 2823 2356 452 31 1456 296 7 2 0 N/A
Croatia EuroA 389100 5610 409 52 3043 1783 1488 285 20 919 187 8 2 0 N/A
Czech Rep. EuroA 547804 7892 575 68 4280 2508 2093 401 26 1294 263 23 7 1 N/A
Denmark EuroA 326007 4413 168 55 2394 1402 1129 117 21 770 157 5 1 0 N/A
Estonia EuroA 78229 1129 82 12 613 359 300 57 5 185 38 2 1 0 N/A
Finland EuroA 299477 4314 314 37 2340 1371 1144 219 14 708 144 7 2 0 N/A
France EuroA 3974436 53589 2019 534 29067 17031 13698 1409 207 9391 1910 61 12 3 N/A
Germany EuroA 3466740 49718 3450 516 26967 15800 13146 2408 200 8192 1666 67 21 4 N/A
Greece EuroA 586137 8500 615 118 4610 2701 2257 430 46 1385 282 35 12 3 N/A
Hungary EuroA 490804 7071 515 61 3835 2247 1875 360 24 1160 236 27 9 1 N/A
Iceland EuroA 23511 339 25 3 184 108 90 17 1 56 11 0 0 0 N/A
Ireland EuroA 358318 5011 282 53 2718 1592 1307 197 21 847 172 4 1 0 N/A
Table 1. (continued)
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Epidemiology and etiology of childhood pneumonia in 2010: estimates for 192 countries
New episodes (incidence) New severe episodes (severe morbidity) Deaths (mortality)
Country
WHO 
Region
Popula-
tion 0–4 
years
All  
ALRI
SP Hib RSV FLU
All  
ALRI
SP Hib RSV FLU
All 
ALRI
SP Hib
RSV, 
FLU*
Israel EuroA 735243 10618 772 113 5759 3375 2818 539 44 1737 353 13 4 1 N/A
Italy EuroA 2901653 41871 3047 418 22711 13307 11109 2127 162 6856 1395 30 10 2 N/A
Luxembourg EuroA 28783 389 15 4 211 124 100 11 1 68 14 0 0 0 N/A
Malta EuroA 19130 278 20 4 151 88 74 14 2 45 9 0 0 0 N/A
Monaco EuroA 2001 29 2 0 16 9 8 1 0 5 1 0 0 0 N/A
Netherlands EuroA 934218 12528 435 126 6795 3981 3192 303 49 2208 449 18 3 1 N/A
Norway EuroA 303047 4085 150 45 2216 1298 1044 105 17 716 146 3 1 0 N/A
Poland EuroA 1933388 27852 2030 241 15107 8851 7388 1417 93 4568 929 126 41 7 N/A
Portugal EuroA 516604 7448 542 69 4040 2367 1976 379 27 1221 248 3 1 0 N/A
San Marino EuroA 1401 20 1 0 11 6 5 1 0 3 1 0 0 0 N/A
Serbia & Montenegro EuroA 604144 8747 634 110 4744 2780 2322 443 43 1428 290 30 10 2 N/A
Slovakia EuroA 275895 3688 123 34 2000 1172 938 86 13 652 133 35 6 2 N/A
Slovenia EuroA 99368 1433 104 14 777 455 380 73 5 235 48 2 1 0 N/A
Spain EuroA 2521375 36353 2647 339 19718 11553 9644 1848 131 5958 1212 50 16 3 N/A
Sweden EuroA 557426 7682 382 72 4167 2441 1989 266 28 1317 268 10 2 1 N/A
Switzerland EuroA 376228 5431 395 56 2946 1726 1441 276 22 889 181 3 1 0 N/A
UK EuroA 3765820 50844 1913 560 27578 16158 13000 1335 217 8898 1810 165 32 10 N/A
Albania EuroB 207681 6230 436 249 3379 1980 1664 304 96 981 200 66 22 14 N/A
Bosnia & Herzegovi-
na EuroB 164958 4784 346 67 2595 1520 1270 242 26 780 159 24 8 2 N/A
Bulgaria EuroB 373095 10245 470 122 5557 3256 2643 328 47 1763 359 219 50 15 N/A
Georgia EuroB 256459 7488 539 143 4061 2380 1990 376 55 1212 247 108 36 12 N/A
Romania EuroB 1079244 32377 2266 1295 17561 10290 8645 1582 501 5100 1037 807 266 172 N/A
FYR Macedonia EuroB 111863 3236 235 39 1755 1029 859 164 15 529 108 10 3 1 N/A
Turkey EuroB 6412702 172393 6203 1724 93506 54786 43984 4330 667 30306 6164 2212 408 126 N/A
Armenia EuroB 226376 6661 475 167 3613 2117 1773 332 65 1070 218 80 26 11 N/A
Azerbaijan EuroB 795163 23855 1670 954 12939 7581 6369 1166 369 3758 764 1448 477 308 N/A
Kyrgyzstan EuroB 595111 17168 1250 166 9312 5456 4555 872 64 2812 572 599 197 35 N/A
Tajikistan EuroB 870519 25144 1828 267 13638 7991 6672 1276 104 4114 837 2097 691 136 N/A
Turkmenistan EuroB 505844 14823 1062 325 8040 4711 3943 741 126 2391 486 824 271 104 N/A
Uzbekistan EuroB 2737750 82133 5749 3285 44549 26102 21929 4013 1272 12938 2632 4970 1638 1057 N/A
Belarus EuroC 514996 30900 2163 1236 16760 9820 8250 1510 479 4868 990 51 17 11 N/A
Kazakhstan EuroC 1640953 94676 6892 914 51352 30088 25117 4811 354 15510 3155 1408 464 83 N/A
Latvia EuroC 115275 6673 484 82 3619 2121 1771 338 32 1090 222 19 6 1 N/A
Lithuania EuroC 166177 9592 698 96 5203 3048 2545 487 37 1571 319 19 6 1 N/A
R. of Moldova EuroC 214693 12557 902 256 6811 3991 3339 629 99 2029 413 161 53 19 N/A
Russian Federation EuroC 8117113 487027 34092 19481 264163 154777 130036 23797 7542 76721 15604 1618 533 344 N/A
Ukraine EuroC 2376293 139669 9980 3376 75756 44387 37167 6966 1307 22460 4568 629 207 87 N/A
ALRI – acute lower respiratory infection, SP – Streptococcus pneumoniae, Hib – Haemophilus influenzae type B, RSV – respiratory syncytial virus, FLU – in-
fluenza virus
*For viral etiologies, N/A indicates that estimates are not available at the national level at this point, due to very little available information and high de-
gree of uncertainty of regional and global estimates.
Table 1. (continued)
the previous two decades in the context of scarcity of in-
formation, and the true morbidity figures for 2010 are like-
ly to be even smaller, ie, less than 0.20 e/cy. In addition, 
the decreasing trend is quite consistent with apparent im-
provements in risk factor prevalence, as recorded by DHS 
and MICS [49,50].
With more evidence, the proportion of pneumonia cases 
that are severe has been revised upward. For HIC, most of 
these estimates were relevant to children hospitalized for 
pneumonia, thus clustering the most severe cases, while 
most studies in LMICs are community–based and encom-
pass a full spectrum of severity. Still, it appears that the in-
crease in the proportion of severe episodes in the LMICs is 
a valid trend, given the high proportion in HICs (which 
may reflect increased proportion of parents seeking care 
and lower threshold for hospitalization). This finding may 
seem paradoxical (ie, that the proportion of pneumonia 
that is severe in nature is higher in high income settings 
that LMIC) and may be explained by a propensity to hos-
pitalize children in HIC or by a faster reduction in pneu-
monia incidence at the community level than in the inci-
dence of severe pneumonia episodes. We could speculate 
that improved social, economic and lifestyle conditions in 
many LMICs over the past decade have a rather major ef-
fect on pneumonia incidence in the whole population, 
while the cases that progress into severe episodes are still 
clustering in the areas with persistent poverty which are 
not really enjoying the benefits of economic growth, so it 
is more difficult to reduce them. If this is true, then the 
proportional contribution of severe episodes to all pneu-
monia episodes in the community is set to continue in-
creasing over time, although both the cases of pneumonia 
in the community and severe cases are being reduced – but 
the former is being reduced at a faster pace than the latter.
It is reassuring that the etiological estimates for SP, Hib, RSV 
and influenza, which were based on entirely different data 
sets from those that were used for the estimates of pneu-
monia incidence, severe morbidity and mortality, and 
which were also conducted independently of each other, 
are all “fitting” into the envelopes of pneumonia incidence, 
severe morbidity and pneumonia deaths at the global, re-
gional and (for SP and Hib) also at the national level [37–
46]. At the level of pneumonia incidence, there is likely a 
multitude of etiological causes that contribute to pneumo-
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nia in the community. Therefore, at the global level, the 
four major pathogens combined explain about 55% of all 
episodes, according to our computations, but this grows to 
considerably more among pneumonia deaths [43–46]. The 
modeling effort does not reveal whether the unattributed 
fractions are likely from these four pathogens or from oth-
er pathogens. As an example, at the level of severe episodes, 
it appears that the four pathogens explain nearly 95% of 
all episodes in Europe and 83% in the Americas, but only 
48% in Eastern Mediterranean region and as little as 39% 
in sub–Saharan Africa. A large ongoing project funded by 
The Gates Foundation – “The Pneumonia Etiology Re-
search for Child Health (PERCH)” study – will try to ex-
plain etiology of childhood pneumonia better at the global 
level [25]. It is a 7–site study in LMICs, coordinated by 
Johns Hopkins University, to determine the etiology, or 
causes, of pneumonia, and the first results are expected in 
the latter part of 2014 [25].
All burden of disease estimates must cope with the issue of 
uncertainty in the data and the estimates. All the estimates 
of childhood pneumonia at either global, regional or (es-
pecially) national levels are inherently uncertain, for the 
many reasons mentioned in the beginning of this paper. 
The evidence to population models remains limited, and 
the case definitions used across studies are not all the same, 
yet the estimates are rather robust. What makes them plau-
sible, if not certain, is that they are internally consistent: 
mutually independent cause–specific etiology estimates 
“fit” into the “envelopes” of total cases, severe cases and 
deaths; in addition, case–fatality rates between incident 
cases and deaths, and severe episodes and deaths, based on 
our model, resemble those observed in real data. This is all 
reassuring, but it also needs to be noted that the estimates 
of uncertainty (presented in Online Supplementary Docu-
ment) are still probably (substantially) under–estimated. 
This is because each and every parameter derived from a 
previous parameter (eg, proportion of all acute lower re-
spiratory infection (ALRI) cases that are SP) has its own 
uncertainty, as do the estimates of vaccine effectiveness, risk 
factor odds ratios, rates of vaccine coverage, and all other 
parameters in the model. We typically expressed only un-
certainty related to each specific parameter, without adding 
the uncertainty of all the previous parameters from which 
the new estimate has been derived. This makes the whole 
table in the Online Supplementary Document seem more 
precise than it actually may be, given that the uncertainties 
are really large, and only the consistency between different 
estimates in the much bigger picture is what gives it some 
credibility with the current amount of evidence. CHERG 
aims to continue identifying new sources of published and 
unpublished good quality data and updating these esti-
mates regularly with this new information and so increase 
the quality of its estimates towards the Millennium Devel-
opment Goal 4 target in 2015 and well beyond, until pre-
ventable childhood diseases are adequately controlled and 
responded to everywhere in the world [57,58].
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